Compare SPRO & FEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | FEAM |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.0M | 56.9M |
| IPO Year | 2017 | 2022 |
| Metric | SPRO | FEAM |
|---|---|---|
| Price | $0.94 | $1.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $5.33 | ★ $5.88 |
| AVG Volume (30 Days) | 320.0K | ★ 359.6K |
| Earning Date | 11-12-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | 63.80 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $66,802,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $81.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 39.24 | N/A |
| 52 Week Low | $0.95 | $0.90 |
| 52 Week High | $3.08 | $4.65 |
| Indicator | SPRO | FEAM |
|---|---|---|
| Relative Strength Index (RSI) | 34.32 | 31.76 |
| Support Level | N/A | $1.37 |
| Resistance Level | $1.27 | $1.99 |
| Average True Range (ATR) | 0.06 | 0.20 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 3.18 | 3.64 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.